What Risorius does

Risorius Co., Ltd. is a South Korean neurotechnology startup founded in 2023 and headquartered in Seoul that develops AI-driven solutions combining EEG and clinical data to quantitatively analyze treatment responses for neurological and psychiatric conditions. The company's core technology stack centers on a proprietary Brain Foundation Model for psychiatric and neurological care, paired with a company-developed EEG device for data acquisition. Risorius is building an AI Co-Scientist platform for central nervous system research across neurology, psychiatry, and sleep indications, and is developing an AI agent targeted at mental and neurological hospitals in the United States.

The company sells to two primary customer verticals: pharmaceutical companies seeking objective, quantitative efficacy measurement for CNS drug development and clinical trials, and hospitals seeking improved diagnostic and treatment-monitoring capabilities for neurological conditions. Revenue model details are not publicly disclosed, but the business operates as a B2B enterprise model with direct sales to pharma and hospital accounts. Partnerships include a strategic data licensing agreement with OneMedNet Corporation (February 2026) for large-scale EEG and polysomnography datasets, and institutional investment from Seoul National University Technology Holdings (January 2026), supporting Risorius's biomarker development pipeline.

The company is led by CEO Bae Sang-yoon, with headcount reported at 11-50 employees. To date, Risorius has completed three funding rounds totaling approximately $734K USD in disclosed investment, with an additional undisclosed investment from Seoul National University Technology Holdings. Products including the AI Co-Scientist platform and US-targeted AI agent remain in development, and no commercial revenue has been disclosed.

Name

Risorius

Legal name

Risorius Co., Ltd.

Website

https://risorius.kr

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

Risorius is a Seoul-based neurotechnology startup that develops AI-driven EEG analysis technology and a proprietary Brain Foundation Model to quantitatively measure treatment responses for pharmaceutical companies and hospitals treating neurological and psychiatric conditions.

Ownership category

akta.pro rank

Product category

Neurotechnology AI / Medical AI Software

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• EEG analysis technology
• Neurotechnology AI
• Digital biomarkers
• Brain foundation model
• CNS research platform

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations

Core offering

Risorius develops AI-driven neurotechnology solutions that combine EEG and clinical data to quantitatively analyze treatment responses for neurological and psychiatric conditions. The offering centers on a proprietary Brain Foundation Model supported by a company-developed EEG device and an AI Co-Scientist platform for CNS research, targeting pharmaceutical companies, hospitals, and US mental/neurological hospitals.

Product overview

Risorius offers an integrated neurotechnology platform centered on its Brain Foundation Model for psychiatric and neurological care. The core offering includes proprietary EEG analysis technology that combines EEG and clinical data to quantitatively analyze treatment responses. The company has completed development of its own EEG device and is developing an AI Co-Scientist platform for CNS research. Risorius targets pharmaceutical companies and hospitals as primary customers, with additional focus on mental and neurological hospitals in the United States through AI agent development.

Differentiator

Problem solved

Functional benefit

Products and services

• Brain Foundation Model

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

One partnership is on record.

• OneMedNet CorporationcoreTechnology or Integration · 24 February 2026OneMedNet Corporation entered a strategic data licensing agreement with Risorius Co., Ltd., granting access to large-scale EEG and polysomnography (PSG) waveform data paired with longitudinal clinical data. The partnership supports Risorius's development of EEG-based digital biomarkers and an AI Co-Scientist platform for central nervous system (CNS) research across neurology, psychiatry, and sleep indications. Data delivery is underway over a three-month project period. The deal represents millions of dollars in incremental recurring revenue for OneMedNet.

Recent moves6 records

Expansion highlights5 records

Direct peers

• Beacon Biosignals: Beacon Biosignals develops EEG-based digital biomarkers and analytics for CNS clinical trials in neurology, psychiatry, and sleep, directly mirroring Risorius's AI Co-Scientist platform and biomarker focus. Both companies compete for pharma-sponsored CNS endpoint contracts.
• Cumulus Neuroscience: Cumulus Neuroscience offers an EEG and digital biomarker platform for CNS clinical trials in neurodegeneration and psychiatry, overlapping with Risorius's biomarker-for-pharma offering. Both target objective CNS endpoints with multimodal biosignal analytics.
• iMediSync: iMediSync is a Korean AI-EEG company developing diagnostic and therapeutic neurotechnology products. It is the closest direct geographic and product peer to Risorius, also combining proprietary EEG hardware with AI for brain health applications.

Broad incumbents

• NeuroPace: NeuroPace is an established neuro-device company with an FDA-cleared closed-loop brain stimulation system for epilepsy. It represents a larger incumbent in the EEG/neurological monitoring space that validates the CNS neurotechnology market Risorius targets.
• Ceribell: Ceribell provides AI-enabled continuous EEG monitoring for hospitalized patients, directly relevant to Risorius's hospital EEG monitoring and AI agent ambitions. It is a broader incumbent with FDA-cleared products and existing hospital channel relationships.
• Compumedics Limited: Compumedics manufactures clinical EEG, PSG, and brain monitoring equipment used in neurology and sleep research. It is a broad incumbent in clinical EEG hardware that Risorius will compete with on hospital sales channels.

Emerging players

• EMOTIV: EMOTIV makes consumer and research-grade EEG hardware combined with brain data analytics, an emerging player in portable EEG. It is comparable to Risorius on the hardware-plus-software model, though oriented more toward consumer and research than clinical diagnostics.
• Neurable: Neurable builds EEG-based brain-computer interface technology for cognitive health and monitoring applications. It overlaps with Risorius on EEG biosignal analysis for brain health, though more focused on consumer wearables than pharma/hospital channels.
• Lin Health: Lin Health (formerly Linus Health) applies AI-driven digital cognitive assessments and brain health analytics, with partial overlap to Risorius in CNS digital biomarker development. It is an emerging player in objective CNS measurement for clinical and research use.

Others

• OneMedNet Corporation: OneMedNet is Risorius's strategic data licensing partner, supplying large-scale EEG and polysomnography datasets. As an enabler of Risorius's biomarker pipeline rather than a competitor, it is a key ecosystem participant.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Risorius